top of page
News, Events and Updates
Search
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau...
Jul 15, 2011
Anavex to Present at Alzheimer's Association International Conference on Alzheimer's Disease
Jul 14, 2011
Anavex Raises $1.575 million
Jul 10, 2011
Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well
Jul 5, 2011
Anavex Advances Second Lead Compound; Initiates Scale-Up Manufacturing of ANAVEX 1-41
Jun 7, 2011
ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease
May 22, 2011
Anavex Comments on New Alzheimer’s Disease Diagnostic Guidelines
May 16, 2011
Anavex Appoints Robert Chisholm to Board of Directors
May 12, 2011
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
May 10, 2011
45
46
47
48
49
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
